Startup profile · funding coverage
Star Therapeutics funding, valuation and investors
Antibody developer rebuilding its pipeline after the sale of Vega Therapeutics.
Keep track of Star Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Private financing (lettered series undisclosed)
$200M · October 23, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$200M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
Stage not recorded · South San Francisco, California, United States
Investors in latest funding
Lead: OrbiMed , Janus Henderson Investors
Other: Agent Capital , Catalio Capital Management , Cormorant Asset Management , New Leaf Venture Partners , NYBC Ventures , RA Capital Management , Redmile , Sofinnova Investments , Soleus Capital
Overview
Star Therapeutics is a South San Francisco antibody developer led by CEO Adam Rosenthal. Its research starts with patient samples and disease biology to select therapeutic targets, with the aim of developing medicines for multiple indications. On October 23, 2026, it announced $200M in private financing co-led by OrbiMed and Janus Henderson Investors to advance preclinical programs toward clinical development and expand its pipeline. The announcement did not identify a lettered series or valuation. Incyte completed its acquisition of Star subsidiary Vega Therapeutics on July 6, 2026, paying $1.25B upfront plus up to $750M tied to sales milestones. That acquisition is separate from Star's new financing; Star remains a private company.
Why Star Therapeutics is interesting
The Vega exit provides evidence of the team's ability to advance a development asset to a pharmaceutical acquisition. Investors are backing another pipeline, but its undisclosed preclinical programs still face clinical, regulatory and capital risks.
Product & use cases
Discovery and development of antibody medicines, using patient samples and disease biology to identify targets. New programs funded in October 2026 are preclinical; targets and program count were not disclosed.
Key facts
- $200M private financing announced October 23, 2026.
- OrbiMed and Janus Henderson Investors co-led the financing.
- Vega sale proceeds and conditional milestones are separate from the new financing.
Funding history (newest first)
Private financing (lettered series undisclosed)
2026-10-23 $200M- OrbiMed (lead)
- Janus Henderson Investors (lead)
- Agent Capital (participant)
- Catalio Capital Management (participant)
- Cormorant Asset Management (participant)
- New Leaf Venture Partners (participant)
- NYBC Ventures (participant)
- RA Capital Management (participant)
- Redmile (participant)
- Sofinnova Investments (participant)
- Soleus Capital (participant)
Investors in our directory
Funds linked from Star Therapeutics's profile — open a fund page for stage focus and related deal articles.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Star Therapeutics's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.